What is East India Pharmaceutical Works Limited?

East India Pharmaceutical Works Limited is one of India's oldest pharmaceutical manufacturers, incorporated in 1936 in Kolkata, West Bengal. The company operates in drug manufacturing and has been part of the Indian pharmaceutical landscape since before Independence. With CIN U24231WB1936PLC008598, it is registered as a West Bengal company in the pharmaceutical manufacturing sector.

How old is East India Pharmaceutical Works Limited?

East India Pharmaceutical Works Limited was incorporated in 1936, making it approximately 88–90 years old as of 2024–2025. This makes it one of the oldest active pharmaceutical companies in India, predating Indian Independence in 1947.

Where is East India Pharmaceutical Works Limited located?

East India Pharmaceutical Works Limited is headquartered in Kolkata, West Bengal. The company has been based in Kolkata since its 1936 incorporation, historically one of India's most important commercial and industrial cities.

Is East India Pharmaceutical Works listed on any stock exchange?

No, East India Pharmaceutical Works Limited is an unlisted company categorized as 'Unlisted' in the unlisted securities market. Its shares trade at approximately ₹39 per share in the unlisted OTC market.

What types of pharmaceutical products does East India Pharmaceutical Works manufacture?

Specific product details are not publicly confirmed. As a drug manufacturer incorporated in 1936 in Kolkata, the company may produce Ayurvedic, Unani, or allopathic formulations including tablets, capsules, liquid medicines, ointments, or other pharmaceutical preparations. Given its legacy, it may also hold manufacturing licenses for older drug formulations.

What is the CIN of East India Pharmaceutical Works?

The CIN of East India Pharmaceutical Works Limited is U24231WB1936PLC008598. The 'U' prefix indicates it is an unlisted company, 'WB' indicates West Bengal registration, '1936' indicates the year of incorporation, and '24231' is the NIC activity code for pharmaceutical preparations manufacturing.

How do I buy East India Pharmaceutical Works unlisted shares here?

Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.

Who am I actually transacting with?

You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.

How do I pay, and is there a payment gateway?

Payment is by direct bank transfer to Prospire Network Private Limited's published account (CIN U82300UP2025PTC233622), shown to you in-app at the payment step. There is no card gateway and no escrow. Never pay to a personal account or to any account shared over phone, WhatsApp or email — even if the person claims to be from our team.

How long does settlement take?

After you accept an allocation, you have a short window to pay (typically 2 days). Once payment is verified, shares are usually credited to your demat within 2–3 business days, subject to depository timelines and any company-level restrictions. Timeframes are typical, not guaranteed.

There are no separate platform fee lines and no GST on the transfer — the desk's margin is built into the buy/sell price you're quoted. The only statutory add-on on a purchase is stamp duty on the consideration, shown transparently in your cost breakdown.

Is there a minimum ticket size for East India Pharmaceutical Works?

Minimums vary by company and depend on the lot the desk can source. Raise an enquiry and the desk will confirm the available quantity and the minimum for that name.

What KYC do I need, and do I need a demat account?

You'll share your demat details when you enquire so we can settle directly. Full KYC — PAN and a client-master / demat statement — is required before the transfer step, when shares actually change hands. Yes, you need an active demat account to hold unlisted shares.

Are there lock-ins on unlisted or pre-IPO shares?

Some shares carry statutory or company-imposed lock-ins — for example, a post-listing lock-in on pre-IPO stock — and transfers can be subject to the company's articles or approvals. Where a lock-in applies, we'll flag it before you commit.

How do I sell East India Pharmaceutical Works shares I already hold?

Raise a sell enquiry with the company, quantity and your target price. The desk confirms a buying price, you transfer your shares into the desk's demat, and once the credit is verified we pay you out by bank transfer to your registered account. The desk never pays out before your shares are received.

Unlisted shares are illiquid, may be hard or impossible to sell, and are not covered by exchange settlement guarantees or investor-protection funds. Pricing is indicative, not live. Read the full Risk Disclosure before you enquire, and invest only what you can afford to lock away.

East India Pharmaceutical Works Unlisted Share Price | Buy East India Pharmaceutical Works Pre-IPO Shares — wisefolio

Unlisted shares are illiquid and carry higher risk than listed securities. Prices are indicative, not live. Read the risk disclosure.

Talk to us

East India Pharmaceutical Works Unlisted Share Price | Buy East India Pharmaceutical Works Pre-IPO Shares — wisefolio | wisefolio

Investment Thesis

East India Pharmaceutical Works Limited is a historically significant pharmaceutical manufacturer incorporated in Kolkata in 1936 — nearly 90 years ago — making it one of the oldest active pharmaceutical companies in India. While its longevity and established market presence in eastern India are genuine assets, the lack of public financial disclosure, minimal digital presence, and competitive pressures from larger organized pharmaceutical manufacturers are significant concerns. At ₹39 per share in the unlisted market, the investment thesis rests primarily on the company's legacy asset base, potential value of accumulated manufacturing licenses and intellectual property, and the fundamental stability of pharmaceutical demand rather than high-growth prospects.

Pros

ISIN INE254X01017 confirmed; revenue ₹249 Cr (FY24) growing 6.7% YoY — large unlisted pharma manufacturer with ₹100-500 Cr scale.
Incorporated April 27, 1936 — 89+ years of pharmaceutical manufacturing heritage; one of India's oldest pharma companies.
EBITDA grew 16.05% in FY24 — strong margin expansion alongside revenue growth; improving operational efficiency.
Diverse pharma portfolio: pharmaceuticals, medicinal chemicals, botanical products — broad therapeutic coverage.

Cons

Unlisted (U-prefix) — no secondary market despite 89 years of operations; limited institutional investor access.
No promoter details publicly confirmed; Duttagupta family in management but shareholding structure unclear.
Pharmaceutical manufacturing faces regulatory pressure from CDSCO/FDA; compliance costs are rising.
Kolkata-based pharma companies face logistics challenges vs. peers in Gujarat/Hyderabad/Pune hubs.

Business Segments

Pharmaceuticals Manufacturing

Manufacturing of pharmaceuticals, medicinal chemicals, and botanical products; one of India's oldest pharma companies with 89+ years of operations.

Revenue Model

East India Pharmaceutical Works Limited generates revenue through the manufacture and sale of pharmaceutical drug formulations to wholesale distributors, chemist networks, hospitals, and institutional purchasers. As a legacy Kolkata-based manufacturer, the company likely serves the eastern India pharmaceutical market through established long-term relationships with distributors. Revenue may also include licensing of manufacturing facilities or contract manufacturing for other pharmaceutical companies. Given the vintage of the company, revenue scale and exact product mix are not publicly confirmed.

Detailed Analysis

Growth outlookExpansion plans, industry tailwinds & headwinds12

Growth Plans

India's healthcare spending growth and expanding pharmaceutical market create ongoing demand for drug manufacturers at all scales

Potential value unlock through legacy land and fixed assets in Kolkata's evolving real estate market

Partnership or contract manufacturing arrangements with larger pharmaceutical companies could leverage existing facilities and licenses

Growing demand for traditional and herbal medicines could align with potential legacy product lines

Recent Developments

Continued unlisted pharmaceutical operations

East India Pharmaceutical Works Limited continues to operate as an unlisted pharmaceutical manufacturer in Kolkata. The company has maintained active corporate status through regulatory compliance with MCA filings and pharmaceutical manufacturing regulations.

Ongoing

Comparable Companies

CompanyTypeTickerMkt Cap

Bengal Chemicals and Pharmaceuticals Limited (BCPL)ListedPSU / Government entity—

Hindustan Unilever (Pharma legacy segment)ListedHINDUNILVRLarge-cap

Calcutta Chemicals Co. LtdListedUnlisted—

Elder Pharmaceuticals (legacy entity)ListedUnlisted/Delisted—

Frequently Asked Questions

About East India Pharmaceutical Works

East India Pharmaceutical Works Limited is one of India's oldest pharmaceutical manufacturers, incorporated on 27 April 1936 in Kolkata during the British colonial era. The company manufactures basic pharmaceutical preparations across multiple therapeutic categories, establishing itself as a heritage pharmaceutical brand in Eastern India over nearly 90 years. With roots in Kolkata's industrial heritage, East India Pharmaceutical Works has operated through India's independence, the post-independence pharmaceutical policy framework, and the modern IP regime. The company is registered under NIC code for manufacture of basic pharmaceuticals, reflecting a comprehensive drug manufacturing mandate. The company reported revenues in the ₹100-500 crore range in FY2024, indicating meaningful operating scale. With authorized capital of ₹10 crore and paid-up capital of ₹6.67 crore, and an active 12-director board including Sukamal Chandra Basu and Dilip Samadar, the company maintains active operations. Kolkata's pharmaceutical sector has a long heritage, producing branded generics for Eastern Indian markets. East India Pharmaceutical Works competes in this legacy pharma space alongside Dey's Medical, Albert David, and other Kolkata-based manufacturers. The company's 88-year track record, if paired with manufacturing quality upgrades, positions it to benefit from India's growing branded generics demand.

Key Milestones

Incorporated April 27, 1936 in Kolkata, West Bengal (CIN: U24231WB1936PLC008598) — 89+ years old

Common questions about unlisted shares

How do I buy East India Pharmaceutical Works unlisted shares here?
Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.
Who am I actually transacting with?
You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.
How do I pay, and is there a payment gateway?

Risk factors & red flagsInvestment risks and items flagged from public filings12

Financial PerformanceMedium

Net profit margin is thin at 1.2% (FY2023-24) — limited buffer against revenue or cost shocks

Source: Financial data

Leverage & DebtLow

Debt-to-equity ratio of 2.70x (FY2023-24) indicates elevated leverage — increases financial risk in downturns

Source: Financial data

Operational RiskLow

Indian pharmaceutical manufacturers are subject to increasingly stringent Good Manufacturing Practice (GMP) norms under the Central Drugs Standard Control Organisation (CDSCO). Older manufacturing facilities may require significant capital investment to meet modern GMP standards.

Source: Regulatory Filings

Fraud / GovernanceLow

India's generic drug manufacturing sector is dominated by large, vertically integrated players with global distribution capabilities. A small, regional manufacturer faces significant competitive pressure on pricing and product range.

Source: Media Reports / Public Records

Fraud / GovernanceLow

Minimal publicly available financial or operational information makes due diligence extremely challenging for potential investors. The absence of a confirmed website and limited MCA disclosure reduce investor confidence.

Source: Media Reports / Public Records

Operational RiskLow

India's DPCO (Drug Prices Control Order) imposes price ceilings on essential medicines. Any expansion of price control coverage to the company's product segments would directly compress margins.

Source: Company Financial Filings

Regulatory / LegalLow

Manufacturing equipment and facilities from an 88-year-old company may require significant modernization investments to remain competitive and compliant with current regulatory standards.

Source: Regulatory Filings

GMP Compliance Risk

Competition Risk

Information and Transparency Risk

Drug Price Control Risk

India's DPCO (Drug Prices Control Order) imposes price ceilings on essential medicines. Any expansion of price control coverage to the company's product segments would directly compress margins.

Asset Obsolescence Risk

Manufacturing equipment and facilities from an 88-year-old company may require significant modernization investments to remain competitive and compliant with current regulatory standards.

East India Pharmaceutical Works Limited

How settlement works

Get price alerts for East India Pharmaceutical Works Limited

Discuss East India Pharmaceutical Works

Similar companies

Other ways to invest